Medigus
7A Industrial Park, Omer, HaMerkaz, 8496500, Israel
Overview
Medical device company focused on innovative endoscopic procedures and devices. Medigus developed an entire endoscopic system for intraluminal treatment of GERD (Gastroesophageal Reflux Disease), one of the most common chronic diseases in the Western world. The endoscopic system for the treatment of GERD - the SRS - combines a miniaturized video camera, a surgical stapler and ultrasonic sights for alignment in a single instrument. The SRS system and its unique flexible endoscope allows gastroenterologists and surgeons to perform endoluminally a true partial anterior fundoplication, thereby revolutionizing the treatment of GERD by eliminating the need for open or laparoscopic surgery - the current standard practice for treating severe GERD. Shifting the GERD treatment from surgery to an endoluminal procedure, without opening the abdominal cavity, is a REVOLUTION. In addition, Medigus designs and manufactures endoscopy systems for partner companies based on its proprietary technologies, which include all necessary elements for performing a wide range of endoscopic procedures such as the world’s smallest video cameras, respective video processors and endoscopy suits, and various types of rigid, semi-flexible and flexible disposable video endoscopes.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Manufacturing
- Medical Device
Investment portfolio
- Safee
Led · Equity · Oct 2021
Safee is a Non-Fungible Token (NFT) technology company operating a social network that allows creators and collectors to create, own, engage, control and trade digital goods. Its stated mission is to expand the reach of NFTs to mass-market buyers and creators, including digital artists, illustrators, photographers, musicians and regular consumer digital content creators. Safee says it simplifies NFT ownership for everyday users by creating a simple, engaging way to apply ownership to personal digital media without requiring a special crypto wallet. The platform enables users to establish originality, foster engagement and exchanges, and monetize their digital creations by turning personal media into NFTs. The company’s website is listed as www.Safee.io. Medigus announced a $400,000 investment in Safee and will hold approximately a 2.5% share in the company.
- Polyrizon
Led · Equity · Nov 2020
Polyrizon develops highly differentiated biological gels, including a unique Biogel aimed at protecting against COVID-19, built on its Capture & Contain platform technology. The platform is intended to prevent allergen and virus intrusion through the upper airways and eye cavities. Polyrizon has an existing reseller and investment relationship with Medigus, which was granted an exclusive license to resell Polyrizon’s products once they receive FDA approval. The company is advancing toward an FDA submission, and a new investment is intended to support that effort. Financially, Medigus currently holds 19.9% of Polyrizon and has signed a non-binding term sheet for an additional investment that would increase Medigus’s stake. There are no operating metrics disclosed in the article.